A study to look at how safe different doses of a new medicine called MTPS9579A were for healthy people to take, and how this medicine was processed through the body

A phase 1, single center, randomized, observer-blinded, placebo-controlled study to evaluated the safety, tolerability, pharmacokinetics, and explore pharmacodynamics effects and immunogenicity of single- and multiple-ascending doses of MTPS9579A in healthy adult subjects

  • Healthy Volunteers
Trial Status:

Completed

This trial runs in
Countries
Trial Identifier:

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      One hundred and six healthy male (n=36) and female (n=70) subjects, between 18-55 years of age, enrolled at a single site in Canada. Some participants (n=42) received a single subcutaneous dose (30, 100, or 300 mg MTPS9579A or placebo). Others (n=40) received 3 doses given once every 4 weeks (5 cohorts, including 150, 300, and 750 mg dose cohorts [subcutaneous MTPS9579A or placebo]; 1800 and 3600 mg dose cohorts [IV infusion MTPS9579A or placebo]). Adverse events (rate and severity) were comparable across the dose-level cohorts, between subjects who received MTPS9579A or placebo; the majority were Grade 1 in severity and judged as not related to the study drug. There were no serious adverse events and no deaths. No safety concerns with respect to the clinical laboratory tests, ECGs, and vital signs were noted.

      Genentech Sponsor
      Phase 1 Phase
      All Gender
      ≥18 Years Age
      Yes Healthy Volunteers

      MTPS9579A is a new medicine intended for the treatment of patients with severe asthma. This study investigated the effects of MTPS9579A when taken by healthy people. Some people got the study medicine while others got a placebo (no medicine) to compare side effects of the treatment with and without the medicine. There were 106 healthy people who took part in this study conducted in Canada.

      Trial Summary

      One hundred and six healthy male (n=36) and female (n=70) subjects, between 18-55 years of age, enrolled at a single site in Canada. Some participants (n=42) received a single subcutaneous dose (30, 100, or 300 mg MTPS9579A or placebo). Others (n=40) received 3 doses given once every 4 weeks (5 cohorts, including 150, 300, and 750 mg dose cohorts [subcutaneous MTPS9579A or placebo]; 1800 and 3600 mg dose cohorts [IV infusion MTPS9579A or placebo]). Adverse events (rate and severity) were comparable across the dose-level cohorts, between subjects who received MTPS9579A or placebo; the majority were Grade 1 in severity and judged as not related to the study drug. There were no serious adverse events and no deaths. No safety concerns with respect to the clinical laboratory tests, ECGs, and vital signs were noted.

      Genentech Sponsor
      Phase 1 Phase
      MTPS9579A Treatments
      None Condition
      Official Title

      A phase 1, single center, randomized, observer-blinded, placebo-controlled study to evaluated the safety, tolerability, pharmacokinetics, and explore pharmacodynamics effects and immunogenicity of single- and multiple-ascending doses of MTPS9579A in healthy adult subjects.

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      Yes Healthy Volunteers

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now